CN1056298C - External use medicine for treating soft tissue injury and its producing method - Google Patents
External use medicine for treating soft tissue injury and its producing method Download PDFInfo
- Publication number
- CN1056298C CN1056298C CN96123078A CN96123078A CN1056298C CN 1056298 C CN1056298 C CN 1056298C CN 96123078 A CN96123078 A CN 96123078A CN 96123078 A CN96123078 A CN 96123078A CN 1056298 C CN1056298 C CN 1056298C
- Authority
- CN
- China
- Prior art keywords
- medicine
- soft tissue
- tissue injury
- water preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000002674 ointment Substances 0.000 claims abstract description 7
- 239000011505 plaster Substances 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 49
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 29
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 16
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 10
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 10
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 9
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 241000157835 Gardenia Species 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 18
- 230000036407 pain Effects 0.000 abstract description 17
- 230000008961 swelling Effects 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 240000001972 Gardenia jasminoides Species 0.000 abstract description 3
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract description 3
- 241000118825 Alkanna tinctoria Species 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 45
- 229940079593 drug Drugs 0.000 description 32
- 230000000694 effects Effects 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 239000000686 essence Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 230000002040 relaxant effect Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 9
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 206010063560 Excessive granulation tissue Diseases 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 210000001126 granulation tissue Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 229960000349 nitrofural Drugs 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 230000000472 traumatic effect Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000009519 contusion Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940040145 liniment Drugs 0.000 description 4
- 239000000865 liniment Substances 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000002565 Open Fractures Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001007 puffing effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 244000111489 Gardenia augusta Species 0.000 description 2
- 235000018958 Gardenia augusta Nutrition 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- XPEJRQSXLRKGBZ-UHFFFAOYSA-N 3-nitrofuran-2-carbaldehyde Chemical class [O-][N+](=O)C=1C=COC=1C=O XPEJRQSXLRKGBZ-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000003044 Closed Fractures Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010059284 Epidermal necrosis Diseases 0.000 description 1
- 208000007356 Fracture Dislocation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101710102916 Ichor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 description 1
- 229960001588 ethacridine Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an externally applied medicine for treating soft tissue injury and a production method thereof. The medicine contains coptis, phellodendron bark, gardenia, alkanna tinctoria, etc., and is produced by alcohol extraction and sterilization for microporous filtering films. The medicine can be made into liquid medicine, ointment, membrane medicine, plaster, atc. The medicine of the present invention has the advantages of safety, no toxicity, good moisture holding performance, obvious therapeutic effect, and wide range of application, and has unique therapeutic effect on clearing heat and detoxication, dispersing swelling and alleviating pain, activating blood circulation to dissipate blood stasis, eliminating necrotic tissues and promoting granulation. The effective rate of the medicine reaches 95.74% according to the statistic analysis of 260 cases. The production method of the present invention has a reasonable design.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of soft tissue injury, specifically is the external Chinese patent medicine of the treatment soft tissue injury made of raw material with the Chinese herbal medicine; The invention still further relates to this medicine production method.
Soft tissue injury is commonly encountered diseases, the frequently-occurring disease of traumatology, and fracture or dislocation equivalent damage often are associated with serious soft tissue injury.Modern medicine mainly adopts the operation debridement to open soft tissue injury, prevents traumatic infection with nitrofural, 75% ethanol, benzalkonium bromide, ethacridine etc. in early days; The protection of external vaseline oil yarn promotes the granulation tissue growth.To closed soft tissue injury then mainly with means such as braking, local freezing naturopathy.The traditional medicine external treatment many based on Chinese medicine loose, cream, tincture, be only applicable to closed soft tissue injury.Through the Chinese medicine documentation retrieval centre's update search of State Administration of Traditional Chinese Medicine China, domestic have the document that uses Chinese medicine water preparation and liniment treated soft tissue injury, but all be that treatment closed soft tissue injury or crude preparation by using are (as the freezing Cape jasmine acid solution of Zhang Shi [for water decoction], orthopedics and traumatology of Chinese medicine magazine 1987; (1): 38; The red Radix Et Rhizoma Rhei liniment of Shang Shi Cape jasmine [being tincture], the Shaanxi traditional Chinese medical science 1994; 15 (6): 256; Young disappear ichor [for tincture], external treatment with Chinese medicine magazine 1995; (4): 11; Hou Shi damage liquefaction film [for containing pure liniment], Chinese traditional Chinese medical science bone injury magazine 1995; 3 (5): 1).
Chinese patent application 92112763 disclosed musk shuhuo essences are tincture, scientific and technological achievement Radix Angelicae Pubescentis liniment (serial number: 787) be external-use oil preparation, all only be applicable to closed soft tissue injury.Up to now, still do not have on the domestic and international market a kind of generally acknowledged, not only be suitable for open soft tissue injury but also be suitable for external Chinese medicine water preparation or ointment, the membrane etc. of closed soft tissue injury.
The shortcoming that the purpose of this invention is to provide the medicine that overcomes present treatment soft tissue injury provides a kind of open soft tissue injury that both can be used for, and is applicable to closed soft tissue injury again, has the medicine for external use of good curative effect.
Another object of the present invention provides the production method of this soft tissue injury curative.
The present invention realizes like this.
The employing medicine be Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi), Alumen, Mentholum as principal agent, the medicine for external use of making, preparation formulation are exterior-applied formulations such as water preparation, ointment, plaster, membrane.After increasing dosage again, also can adopt dosage forms for oral administration such as tablet, capsule, oral liquid, electuary.
When preparation of the present invention is the external water preparation, can adopt tween, arabic gum, tragakanta, glycerol etc. to make suspending agent (solubilizing agent), be good with glycerol, because glycerin preparation on spreading upon skin the time, has moisture-keeping function concurrently.
Water preparation of the present invention can also add antiseptic, as parabens, benzoic acids or phenols, is good with ethylparaben (being ethyl hydroxybenzoate) wherein.
Also can add Percutaneous absorption enhancer such as azone (azone) in the preparation of the present invention.
Medicine of the present invention is made (consumption is a weight ratio) by following component: 10～20 parts of Rhizoma Coptidis, 8～15 parts of Cortex Phellodendris, 8～15 parts of Fructus Gardeniaes, 8～15 parts of Radix Arnebiae (Radix Lithospermi)s, 2～5 parts of Alumens (Alumen), 0.05～0.1 part of Mentholum.
The preferential weight ratio scope of medicine of the present invention is: 12～18 parts of Rhizoma Coptidis, 10～12 parts of Cortex Phellodendris, 10～12 parts of Fructus Gardeniaes, 10～12 parts of Radix Arnebiae (Radix Lithospermi)s, 3～4 parts of Alumens (Alumen), 0.07～0.08 part of Mentholum.
The best proportioning of medicine external water preparation of the present invention is: Rhizoma Coptidis 15.96kg, Cortex Phellodendri 11.4kg, Fructus Gardeniae 11.4kg, Radix Arnebiae (Radix Lithospermi) 11.4kg, Alumen 3.42kg, Mentholum 0.09kg, glycerol 45.87kg, ethylparaben 0.46kg add water and are made into 230～920 premium on currency agent.
The production method of medicine external water preparation of the present invention is:
(1) get Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae pulverizing, add 10 times of amount 70% alcohol heating reflux 2 times,
Filter, filtering residue discards;
(2) get Radix Arnebiae (Radix Lithospermi) in addition and be cut into 1～2cm segment, add 10 times of amount 70% alcohol at normal temperature and soak 2 times,
Filter, filtering residue discards;
(3) Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) filtrate are merged, 60～80 ℃ of decompression recycling ethanols add Alumen to the greatest extent;
(4) get Mentholum, ethylparaben and add after with a small amount of 95% dissolve with ethanol, capacity transfer fully stirs to 90～93% of capacity, leaves standstill 24 hours in 0～4 ℃, and filter press adds glycerol again, fully stirs;
(5) use the microporous filter membrane degerming, aseptic subpackaged, get product.
Pondage to capacity 90～93% after, regulating pH is between 3.7～4.0.
The aperture of microporous filter membrane is 0.45 μ m.
Solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to falling the etiology and pathogenesis of pouncing on wound, by the theory of Chinese medical science prescription, filter out one group of Chinese herbal medicine of heat-clearing and toxic substances removing, reducing swelling and alleviating pain, blood circulation promoting and blood stasis dispelling, putrefaction-removing granulation-promoting effect, according to the modern pharmacological research achievement, adopt the preparation process of science and a kind of medicine for external use for the treatment of opening and closed soft tissue injury of developing.Said preparation is reused Rhizoma Coptidis with heat-clearing and toxic substances removing, the dampness detumescence; Help the merit of Rhizoma Coptidis heat-clearing and toxic substances removing, dampness detumescence with Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi), Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) are held concurrently can removing heat from blood and promoting blood circulation, promotes blood circulation to change block up; Alumen detoxifcation putrefaction removing, the convergence granulation promoting; The hot cold of Herba Menthae is loose wind-expelling pain-stopping, and the energy that helps the Radix Arnebiaeization block up to promote blood circulation with light clear a surname.We's prescription is rigorous, makes a distinction between the important and the lesser one, and plays the merit of heat-clearing and toxic substances removing, reducing swelling and alleviating pain, blood circulation promoting and blood stasis dispelling, putrefaction-removing granulation-promoting altogether.Cure mainly pain caused by ecchymoma that various traumatic injury cause, hemorrhage; And to because of invade in wind (heat) poison the rotten blood of (burn and scald) or stagnation of blood stasis and heat, meat lose the soft tissue that causes red, swollen, hot, bitterly in addition disease such as suppuration ideal curative effect is arranged.Through modern pharmacological research, this medicine has infection, antiinflammatory, analgesia, the growth of promotion wound surface granulation tissue, microcirculation disturbance is had a better role, no obvious toxic and side effects, and curative effect is fast.
Narrate embodiment below.
Embodiment 1
Take by weighing raw material by following proportioning: Rhizoma Coptidis 35kg, Cortex Phellodendri 25kg, Fructus Gardeniae 25kg, Radix Arnebiae (Radix Lithospermi) 25kg, Alumen 7.5kg, Mentholum 0.2kg, glycerol 100.55kg, ethylparaben 1kg, make 1000000ml.
Get the granule that Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae are ground into the Semen Glycines size, add 10 times of amount 70% alcohol heating reflux 2 times, each 1 hour, filter, filtering residue discards; Other gets Radix Arnebiae (Radix Lithospermi) is cut into 1～2cm segment, and add 10 times of amount 70% alcohol at normal temperature and soak 2 times, each 24 hours, filter, filtering residue discards; Merge above filtrate, 65 ℃ of decompression recycling ethanols are to most.Add Alumen; Getting Mentholum, ethylparaben adds after with a small amount of 95% dissolve with ethanol; Capacity transfer is to 92% of capacity, and transferring pH is 3.85, fully stirs, and leaves standstill 24 hours in 0～4 ℃, and filter press stirs behind the glycerol adding; After the microporous filter membrane degerming of 0.45 μ m, aseptic subpackaged, the aluminium lid press seal promptly.
Embodiment 2
Rhizoma Coptidis 16kg, Cortex Phellodendri 11kg, Fructus Gardeniae 11kg, Radix Arnebiae (Radix Lithospermi) 11kg, Alumen (Alumen) 3.5kg, Mentholum 0.09kg, preceding four liquid medicine are carried, and concentrate, and add back two medicines, add water solublity or emulsion-type ointment base, make ointment.
Embodiment 3
Rhizoma Coptidis 10kg, Cortex Phellodendri 8kg, Fructus Gardeniae 8kg, Radix Arnebiae (Radix Lithospermi) 15kg, Alumen 5kg, Mentholum 0.1kg, preceding four liquid medicine are carried, and concentrate, and add back two medicines, add plaster substrate, make black plaster or rubber ointment.
Embodiment 4
Rhizoma Coptidis 20kg, Cortex Phellodendri 8kg, Fructus Gardeniae 15kg, Radix Arnebiae (Radix Lithospermi) 8kg, Alumen 3kg, Mentholum 0.05kg, preceding four liquid medicine are carried, and concentrate, and add back two medicines, mix with the filmogen serosity, make membrane according to a conventional method.
Embodiment 5
Rhizoma Coptidis 15.96kg, Cortex Phellodendri 11.4kg, Fructus Gardeniae 11.4kg, Radix Arnebiae (Radix Lithospermi) 11.4kg, Alumen 4.2kg, Mentholum 0.09kg, glycerol 45.87kg, ethylparaben 0.46kg are made into 460 premium on currency agent.
This production method is seen the production method that goes up the external water preparation.
Embodiment 6
Dosage and production method add water and are made into 920 premium on currency agent with embodiment 5.
Rhizoma Coptidis of the present invention, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) also available water are carried.
The administrated method of medicine of the present invention is that the drug ointment agent is applied to affected part (comprising wound surface and closure creation affected part), every day 1～3 time, as be plaster and membrane, then be affixed on the affected part.Every day 1 time.As be water preparation, soak into medicinal liquid with gauze, the external application affected part bandages, and changes dressings every day 1 time, and 20 days is a course of treatment.
An important feature of medicine of the present invention is that pharmacological action is extensive, has:
(1) anti-infectious function.Embodiment 5 and the pyogenic infection of 6 pairs of caused by Staphylococcus aureus mouse skins of embodiment have the obvious treatment effect, and the pathological changes index of infection is obviously reduced, and the necrosis that obviously reduces epidermis, corium, hypodermic necrosis and the appendages of skin destroys.Common traumatic infection pathogen and conditioned pathogen all there is in various degree antibacterial action, wherein stronger to staphylococcus aureus, staphylococcus epidermidis and beta hemolytic streptococcus effect, see Table 1～4, the experimental result prompting: this medical instrument has the effect of heat-clearing and toxic substances removing putrefaction removing.
The table 1. pair caused by Staphylococcus aureus mouse skin pyogenic infection pathological changes information slip (index of group medicine infection lesion (score) of X ± S)
The 3rd day the 5th day the 7th day the 9th day the 11st day physiology saline-2.53 ± the the 0.64th 2.80 ± 0.68 2.77 ± 0.73 2.45 ± 0.52 1.55 ± 0.52 of concentration (%)
(15) (15) (15) (15) (15) muscles relaxing essence 100 2.00 ± 0.53* 2.13 ± 0.35** 2.13 ± 0.35** 1.60 ± 0.51** 0.93 ± 0.73**
(15) (15) (15) (15) (15) embodiment 6 2.33 ± 0.49 2.33 ± 0.62 2.07 ± 0.27**, 1.21 ± 0.47**, 0.89 ± 0.41**
(15) (15) (15) (15) (15) embodiment 5 1.47 ± 0.52** 1.33 ± 0.49** 0.73 ± 0.59** 0.40 ± 0.63** 0.27 ± 0.64**
(15) annotate (15) (15) (15) (15): 1. be number of animals in ().
2. compare * P＜0.05, * * P＜0.01 with the normal saline group.
3. the normal saline group is overweight because of infecting in the experiment, 4 dead mouses, and embodiment is 1 death for 6 groups.
(X ± S) group medicine number of animals dermal pathology changes (score) in the influence of table 2. pair caused by Staphylococcus aureus pyogenic infection mice affected skin pathological change
Concentration, (%), downright bad subcutaneous downright bad attached downright bad physiological saline-11 4.0 ± 0 4.0 ± 0 1.6 ± 0.8 4.0 ± 0 muscles relaxing essence, 100 15 3.2 ± 0.4**, 1.8 ± 0.8**, 1.2 ± 0.4 1.2 ± 0.4** embodiment, 6 14 2.6 ± 0.5**, 1.4 ± 0.5**, 1.1 ± 0.4 1.1 ± 0.4** embodiment, 5 15 2.4 ± 0.7**, 1.5 ± 0.5**, 1.0 ± 0.4*, the 1.0 ± 0.2** that destroys that suppurates that suppurates of (only) Epidermal necrosis suppuration corium annotates: 1. skin pathological changes standards of grading:
"-" expression is normal, gets 0 fen;
"+" expression extent of disease got 1 fen in below 1/4 of the visual field;
" ++ " expression extent of disease accounts for about 2/4 of the visual field, gets 2 fens;
" +++" represent that extent of disease accounts for about 3/4 of the visual field, got 3 fens;
" ++ ++ " represent that extent of disease involves whole visual field, got 4 fens.
2. compare * P＜0.05, * * P＜0.01 with the normal saline group.
Table 3. pair caused by Staphylococcus aureus pyogenic infection mice affected skin fiber
The influence of hamartoplasia (X ± S)
Group drug level (%) number of animals (only) fibroplasia (score) normal saline-11 0.1 ± 0.3 muscles relaxing essence 100 15 1.0 ± 0.5** embodiment 6 14 1.1 ± 0.6** embodiment 5 15 1.3 ± 0.5** annotates: 1. fibroplasia is divided into level Four:
"-" expression whole visual field is not seen hypertrophy, gets 0 fen;
"+" expression hypertrophy scope got 1 fen in below 1/4 of the visual field;
" ++ " expression hypertrophy scope accounts for about 2/4 of the visual field, gets 2 fens;
" +++" represent that the hypertrophy scope accounts for about 3/4 of the visual field, gets 3 fens;
" ++ ++ " represent that the hypertrophy scope involves whole visual field, gets 4 fens.
2. compare * P＜0.05, * * P＜0.01 with the normal saline group.
Table 4. traumatology yellow fluid is to the antibacterial evaluation of traumatic infection encountered pathogenic bacteria and conditioned pathogen
Inhibitory potency
Medicine
The B-mode mucositis large intestine of golden yellow epidermis first type green pus white
Staphylococcus staphylococcus streptococcus streptococcus coccus bacillus bacillus candidiasis embodiment 5,61: 80 1: 40 1: 20 1: 40 1: 10 1: 51: 51: 5 musk shuhuo essences 1: 51: 51: 51: 51: 2.5 1: 2.5 1: 2.5 1: 2.5
(2) antiinflammatory action is arranged.5,6 pairs of histamines of embodiment induced mice capillary of skin permeability increases inhibitory action, and can suppress the mice ear due to the dimethylbenzene; Foot swelling due to embodiment 5,6 PARA FORMALDEHYDE PRILLS(91,95)s and the Ovum Gallus domesticus album has inhibitory action, and see Table 5～8, results suggest: embodiment has the detumescence effect.
Table 5. pair histamine induced mice capillary of skin permeability affect group drug concentration (%) number of animals (only) fibroplasia (score) physiological saline-10 0.359 ± 0.092 muscles relaxing essence 100 10 0.289 ± 0.091 ten thousand caul-fat 100 10 0.171 ± 0.089** embodiment 6 10 0.256 ± 0.071* embodiment 5 10 0.192 ± 0.063**
Annotate: compare * P＜0.05, * * P＜0.01 with the normal saline group.
Table 6. xylol induced mice ear swelling influence the group drug level, (%) number of animals, (only) fibroplasia, (score) normal saline-12 39.6 ± 13.2 muscles relaxing essence 100 10 25.7 ± 13.1* embodiment 6 10 22.1 ± 14.6* embodiment 5 10 22.4 ± 10.9**
Annotate: compare * P＜0.05, * * P＜0.01 with the normal saline group.
The influence of table 7. pair rat Ovum Gallus domesticus album foot swelling
The medicine number of animals causes the scorching back foot swelling degree (group of X ± S)
Concentration, (%), (only) 1 hour 2 hours 5 hours physiological saline-11 0.877 ± 0.135 0.759 ± 0.167 0.391 ± 0.113 muscles relaxing essence 100 10 0.830 ± 0.170 0.695 ± 0.110 0.385 ± 0.120 ten thousand caul-fat 100 10 0.715 ± 0.118** 0.610 ± 0.120*, 0.235 ± 0.103** embodiment, 6 10 0.895 ± 0.145 0.735 ± 0.143 0.355 ± 0.103 embodiment 5 10 0.785 ± 0.167 0.635 ± 0.143 0.285 ± 0.112
Annotate: compare * P＜0.05, * * P＜0.01 with normal saline.
The influence of table 8. pair rat formaldehyde foot swelling
The medicine number of animals causes the scorching back foot swelling degree (group of X ± S)
Concentration, (%), (only) the 2nd day the 3rd day the 4th day the 5th day physiology salt solution-10 0.770 ± 0.158 0.530 ± 0.140 0.390 ± 0.129 0.351 ± 0.101 muscles relaxing essence 100 10 0.641 ± 0.186 0.310 ± 0.097**, 0.230 ± 0.042**, 0.180 ± 0.092** embodiment, 6 10 0.630 ± 0.155 0.450 ± 0.108 0.320 ± 0.123 0.330 ± 0.123 embodiment 5 10 0.570 ± 0.160** 0.330 ± 0.059**, 0.220 ± 0.111**, 0.160 ± 0.117**
Annotate: compare * * P＜0.01 with the normal saline group.
(3) this medicine has certain analgesic activity.Embodiment 5,6 can reduce because of injection due to the formaldehyde little damaged by rats or lick sufficient accumulated time, the trend that the hot plate method proof has the threshold of pain that makes mice to improve, see Table 9～10, results suggest: embodiment has analgesic effect.
Table 9. pair thermostimulation induced mice pain affect pain threshold behind group drug concentration (%) number of animals (only) medicine (%, physiological saline-12 89.6 ± 23.6 muscles relaxing essence 100 10 104.1 ± 17.3 ten thousand caul-fat 10 121.8 ± 14.5** embodiment 6 10 102.7 ± 20.4 embodiment 5 10 107.3 ± 17.5 of X ± S)
Annotate: compare * * P＜0.01 with the normal saline group.
(the group drug level number of animals (only) of X ± S) is licked or is stung sufficient accumulated time in the influence of table 10. PARA FORMALDEHYDE PRILLS(91,95) induced mice foot pain
(%) (second, normal saline-11 72.4 ± 11.7 muscles relaxing essence 100 10 58.0 ± 11.5* embodiment 6 10 66.3 ± 14.7 embodiment 5 10 60.5 ± 11.5* of X ± S)
Annotate: compare * P＜0.05 with the normal saline group.
(2) has the outgrowth effect of the local organization of promotion.Embodiment 5,6 can obviously promote the partial proliferation of fibrous tissue of pyogenic infection mice affected skin of caused by Staphylococcus aureus, 5 pairs of rat cotton balls of embodiment granuloma hypertrophy has the tendency of promotion, see Table 11, results suggest: embodiment has promoting muscle growth functions.
(X ± S) group drug concentration (%) number of animals (only) granuloma weighs (mg/100g body weight) physiological saline-10 191.2 ± 36.1 muscles relaxing essence 100 9 201.3 ± 36.0 hydrocortisones 100 9 101.0 ± 27.9** embodiment 6 50 9 201.4 ± 14.6 embodiment 5 100 9 221.2 ± 31.5 in the table 11. pair granulomatous impact of rat cotton balls
Annotate: compare * * P＜0.01 with the normal saline group.
(5) have the growth of the wound surface of promotion granulation tissue, accelerate the effect of wound repair.By dynamic observing of experimental wound granulation tissue model shown: it is totally smooth that embodiment 5,6 forms mouthful outward appearance, and color and luster is fresh and tender, and the part wound has the yellowish-brown crust to cover; See under the Electronic Speculum that fibroblast quantity is many in the granulation tissue, mitochondrion increases, rough endoplasmic reticulum is abundant, poly and free ribosome increase, tangible Golgi body occurs, collagen fiber are synthetic vigorous, and hydroxyproline content is apparently higher than the normal saline group in the granulation tissue, see Table 12～13, results suggest: embodiment 5,6 has the into function of wound granulation tissue reparation.
Table 12. embodiment, nitrofural and normal saline are to rat implementation granulation group
The real soft peculiar smell nothing of the fresh and tender sallow quality of impact (postoperative 3,4 weeks) the wound outward appearance embodiment 5 nitrofurazone physiological saline surface clean not whole color and luster of smooth clean smooth filth or a little obvious purulent secretion nothing of knitting outward appearance have crust to have or not nothing
Table 13. embodiment 5, nitrofural and normal saline are to the influence of hydroxyproline content in the granulation tissue
(mg/g, the 3rd week of the 2nd week the 1st week of the group of X ± S) the 4th all embodiment 5 10.20 ± 1.58** 19.51 ± 1.18** 23.88 ± 1.21 23.96 ± 0.82**## nitrofurals 7.03 ± 0.89## 15.84 ± 1.16## 23.50 ± 1.37## 26.37 ± 1.18 normal saline 3.45 ± 0.46 5.16 ± 0.83 11.01 ± 0.92 12.66 ± 0.84
Compare with same time nitrofural group * P＜0.01;
Compare with same time normal saline group ##P＜0.01.
(6) this medicine has a better role to experimental microcirculation disturbance, due to 5,6 pairs of epinephrines of embodiment in the lagophthalmos bulbar conjunctiva blood capillary flow velocity of blood flow slow down and the minimizing of flow all improves significantly, and can increase the opening of capillary network, see Table 14～15.Results suggest: embodiment 5,6 has the effect of blood circulation promoting and blood stasis dispelling.
The influence of 5,6 pairs of point of intersect of the capillary network countings of table 14. embodiment
Point of intersect of the capillary network (bar, the group number of animals (only) of X ± S)
Distilled water 7 5.867 behind the medicine prodrug ± 1.958 5.857 ± 1.355654-2 7 6.428 ± 2.718 10.428 ± 3.659* embodiment 67 6.000 ± 1.603 9.000 ± 1.603** embodiment 57 4.142 ± 0.833 7.143 ± 0.833**
Annotate: self compare * P＜0.05, * * P＜0.01 before and after each organizes administration.
Microcirculation change situation before the table 15-1. administration (X ± S, n=7)
Group before the administration
V (mm/s) D (μ m) S (μ m
2) Q (* 103 μ m
3/ s) distilled water 0.23 ± 0.06 9.00 ± 3.92 81.43 ± 56.21 19.00 ± 14.27654-2 0.21 ± 0.05 8.17 ± 1.48 60.71 ± 19.39 13.57 ± 7.12 embodiment 6 0.20 ± 0.03 9.57 ± 2.26 75.34 ± 36.87 14.29 ± 5.44 embodiment 5 0.19 ± 0.08 10.14 ± 3.48 97.51 ± 46.39 18.00 ± 8.28
Microcirculation change situation after the table 15-2. administration (X ± S, n=7)
Group before the administration
V (mm/s) D (μ m) S (μ m
2) Q (* 103 μ m
3/ s) distilled water 0.22 ± 0.08 8.86 ± 3.98 79.71 ± 57.31 16.86 ± 13.72654-2,0.27 ± 0.05* 10.71 ± 2.21 93.29 ± 38.71 24.30 ± 8.90* embodiment, 6 0.32 ± 0.06**, 9.43 ± 2.66 74.86 ± 39.91 22.43 ± 9.98 embodiment 5 0.31 ± 0.09** 11.86 ± 1.73 111.14 ± 42.27 34.71 ± 19.10*
Annotate: self compare * P＜0.05, * * P＜0.01 before and after each organizes administration.
Another important feature of medicine of the present invention is no obvious toxic and side effects.
(1) embodiment acute toxicity test
This experimental observation 5 pairs of animal intact skins of embodiment and damaged skin short time or repeat to smear toxicity, skin irritation and the anaphylaxis situation that administration produces.Result of the test as seen, 5 pairs of white rabbit intact skins of embodiment and damaged skin irritant reaction and matched group relatively, difference is not obvious, does not see that also abnormal change appears in animal; White guinea pig skin repeat administration was not met quick reaction.Seeing Table 16～17 shows normal and damaged skin nonirritant; Normal and the damaged skin administration to animal, no acute toxic reaction; Repeat to smear administration and do not see the generation sensitization.
5 pairs of skin irritant average response values of table 16. embodiment
Number of animals integration summation average response value
Group
(only) 1 24 48 (h) 1 24 48 (h) shone damaged skin 4440110 little intact skin 4000000 dosage damaged skins 4440110 big intact skin 4000000 dosage damaged skins 4440110 to intact skin 4000000
5 pairs of guinea pig skin influences hypersensitive of table 17. embodiment
Mus is counted average response value sensitization rate group
(only) 6 24 48 72 (h) (%) contrasts 10 00000 positive 10 1 0.95 0.80 0 100 embodiment 5 10 00000
(2) embodiment long term toxicity test
Heavy dose of administration 42 days is not seen and is caused animal appearance, behavioral activity, and food ingestion, just large and small, the hematology, blood biochemical is learned and the pathologic of important organ changes, and sees Table 18～23, shows traumatology yellow fluid safety non-toxic, can use for clinical trial.
Respectively organized the variation (14d after the group sex od 20d 42d drug withdrawal of X ± S) of rat body weight after table 18. embodiment administration 42 days and the drug withdrawal in 14 days
The intact contrast in ♀ 174.00 ± 8.43 230.50 ± 16.06 256.50 ± 14.30 281.20 ± 17.43
♂ 184.50 ± 7.97 276.50 ± 17.48 327.00 ± 30.65 359.43 ± 25.41 whole ♀ 171.50 ± 7.09 233.00 ± 19.46 253.88 ± 15.76 279.76 ± 18.36 low dosage skin ♂, 182.00 ± 7.98 269.50 ± 21.46 316.50 ± 36.43 352.31 ± 35.10 skin ♀ 170.28 ± 10.16 220.50 ± 19.01 246.00 ± 20.81 272.63 ± 24.21 high doses
♂?185.02±6.32 264.50±17.67 312.00±26.26 346.82±31.32
The broken contrast in ♀ 172.10 ± 7.24 228.46 ± 15.46 252.80 ± 16.40 276.19 ± 16.41
Decrease ♂ 180.42 ± 8.32 274.40 ± 16.21 317.21 ± 28.26 351.26 ± 19.93
♀ 170.92 ± 6.82 228.12 ± 17.12 250.21 ± 16.49 270.42 ± 20.41 low dosage skin ♂ 183.24 ± 9.21 265.50 ± 18.21 310.43 ± 19.21 348.21 ± 16.49
♀ 174.25 ± 6.42 218.42 ± 17.43 240.19 ± 18.41 266.45 ± 24.31 skin high doses
♂?179.41±8.24 260.82±18.58 300.12±24.81 342.92±20.45
The variation of table 19-1 percutaneous drug delivery rat blood index after 42 days (X ± S)
Group RBC HGB RRBC PLT
(×10
12/L) (g/L) (％) (×10
9/L)
Contrast 7.63 ± 0.58 145.30 ± 5.80 2.03 ± 0.53 838.20 ± 89.36 complete low dosages 7.25 ± 0.74 141.30 ± 8.51 2.10 ± 0.40 881.21 ± 98.24 skin high dose 7.24 ± 0.61 140.10 ± 4.38 1.87 ± 0.51 876.38 ± 94.53
Contrast 7.42 ± 0.64 140.41 ± 6.62 2.23 ± 0.72 902.24 ± 100.43 damaged low dosages 7.01 ± 0.72 138.49 ± 7.21 2.43 ± 0.49 892.41 ± 98.92 skin high dose 7.31 ± 0.45 142.24 ± 5.42 2.51 ± 0.81 884.00 ± 112.41
Table 19-2
Group WBC LYMPH MO+GR CT
(×10
9/L) (％) (％) (min)
Contrast 13.81 ± 4.21 75.40 ± 6.70 24.60 ± 5.70 3.20 ± 1.20 complete low dosages 13.48 ± 3.21 77.85 ± 5.21 22.15 ± 4.30 3.41 ± 1.41 skin high doses 13.59 ± 2.93 74.20 ± 6.80 25.80 ± 2.40 3.01 ± 1.50
Contrast 13.60 ± 5.10 78.20 ± 5.10 21.80 ± 3.10 3.43 ± 1.82 damaged low dosages 13.76 ± 5.92 76.80 ± 4.20 23.20 ± 3.21 3.61 ± 1.96 skin high doses 13.90 ± 4.12 80.00 ± 6.28 20.00 ± 4.00 3.21 ± 1.63
The variation of table 20-1 administration rat blood biochemical indexes after 42 days (X ± S)
Group ALT AST ALP TP ALB
(u/L) (u/L) (u/L) (g/L) (g/L)
Contrast 41.21 ± 10.24 159.21 ± 19.29 147.30 ± 26.27 67.20 ± 2.79 35.80 ± 4.48 complete low dosages 38.42 ± 12.41 153.10 ± 17.50 130.82 ± 48.49 66.20 ± 3.53 40.61 ± 3.01 skin high doses 39.21 ± 9.24 142.30 ± 18.94 132.00 ± 63.14 64.90 ± 4.34 39.20 ± 3.40
Contrast 42.46 ± 12.64 151.43 ± 18.43 138.62 ± 52.21 65.20 ± 3.45 34.21 ± 3.28 damaged low dosages 39.21 ± 10.41 144.26 ± 16.72 131.24 ± 38.42 62.92 ± 4.21 32.48 ± 4.01 skin high doses 39.81 ± 8.14 154.27 ± 10.12 140.08 ± 40.01 61.90 ± 4.82 31.82 ± 2.31
Table 20-2
Group GLU T-CHO T-BIL BUN Cr
(mmol/L) (mmol/L) (μmol/L) (mmol/L) (μmol/L)
Contrast 8.06 ± 0.54 4.07 ± 0.81 0.89 ± 0.61 7.89 ± 2.20 65.50 ± 8.24 complete low dosages 7.86 ± 0.96 3.97 ± 0.54 1.95 ± 0.92** 7.71 ± 1.08 68.50 ± 8.27 skin high doses 7.64 ± 0.84 3.92 ± 0.85 2.79 ± 0.69** 6.96 ± 1.76 72.80 ± 11.25
Contrast 7.81 ± 0.68 3.06 ± 0.19 0.95 ± 0.69 6.21 ± 0.73 54.34 ± 7.57 damaged low dosages 7.59 ± 0.48 3.12 ± 0.22 2.06 ± 0.98** 6.51 ± 0.64 52.52 ± 7.79 skin high dose 7.21 ± 0.62 3.01 ± 0.24 2.72 ± 1.21** 6.25 ± 0.76 56.48 ± 9.14
Annotate: compare * p＜0.05, * * p＜0.01 (down together) with matched group
The variation of table 21-1 percutaneous drug delivery each main organs coefficient of rat after 42 days (X ± S)
Organ coefficient (g/100g body weight)
Group
Conscience spleen lung kidney
Contrast 0.31 ± 0.04 3.49 ± 0.41 0.37 ± 0.15 0.59 ± 0.09 0.69 ± 0.08 complete low dosage 0.32 ± 0.04 3.75 ± 0.42 0.37 ± 0.10 0.54 ± 0.07 0.68 ± 0.08 skin high dose 0.31 ± 0.03 3.85 ± 0.43 0.37 ± 0.08 0.53 ± 0.06 0.74 ± 0.07
Contrast 0.30 ± 0.03 3.31 ± 0.45 0.36 ± 0.10 0.58 ± 0.08 0.62 ± 0.08 damaged low dosage 0.29 ± 0.04 3.26 ± 0.38 0.34 ± 0.07 0.59 ± 0.09 0.60 ± 0.07 skin high dose 0.29 ± 0.03 3.43 ± 0.40 0.35 ± 0.07 0.56 ± 0.10 0.58 ± 0.06
Table 21-2 group organ coefficient (g/100g body weight)
Intact contrast 0.14 ± 0.04 0.021 ± 0.008 0.45 ± 0.10 0.21 ± 0.04 whole skin low dosage 0.13 ± 0.03 0.023 ± 0.009 0.47 ± 0.11 0.24 ± 0.03 skin of thymus adrenal gland prostate seminal vesicle uterus ovary
Skin low dosage 0.10 ± 0.03 0.019 ± 0.008 0.50 ± 0.11 0.27 ± 0.12 skin is decreased in the broken contrast 0.11 ± 0.03 0.020 ± 0.007 0.52 ± 0.10 0.26 ± 0.09 in high dose 0.13 ± 0.04 0.021 ± 0.008 0.45 ± 0.06 0.24 ± 0.05
High dose 0.10 ± 0.03 0.021 ± 0.09 0.48 ± 0.12 0.25 ± 0.11
Table 22. embodiment percutaneous drug delivery is rat liver tissue slice check result after 42 days
Downright bad companion's cell infiltration degeneration (endochylema is loose)
Group n
-+++ +++-+++ ++ skin high dose 10 36105131 notes are decreased in+complete contrast 10 35116031 whole skin high dose 10 44205122 broken contrasts 10 25215212: (1) necrosis: "+" is dispersed in point-like or little focal necrosis for minority;
"+" is light starlike distribution all over the sky for spotty necrosis;
" ++ " is that downright bad Caulis et folium pavettae hongkongensis distributes.
(2) degeneration: 1/3 of every lobule is involved for the endochylema puffing in "+";
" ++ " be every lobule 1/3～1/2 for the endochylema puffing involves;
" +++" endochylema puffing involves more than 1/2 of every lobule.
(3) low dosage is 20 times of clinical consumption, and high dose is 60 times of clinical consumption.
Acute and sub-acute toxicity test shows that this medicine of short-term or life-time service is not seen and caused animal appearance, behavioral activity, food ingestion, just large and small, the hematology, blood biochemical is learned and the pathologic of important organ changes, and shows the embodiment safety non-toxic, can use for clinical trial.
(4) clinical adverse is observed
Show that by the inspection to blood pressure, routine blood test, Cr, BUN, GPT, bilirubin metabolism before and after 60 routine patient's medications the human physiological functions of 5 pairs of above-mentioned projects of embodiment is harmless, sees Table 23, the clinical practice that shows embodiment is safe.
Table 23. embodiment is to the influence of indexs such as patient's blood pressure, hepatic and renal function
After checking the preceding medication of group medication before the experiment
Treatment group (32) 14.54 ± 1.40 14.06 ± 1.12# systolic pressures (KPa)
Matched group (28) 14.54 ± 1.58 14.09 ± 1.16
Treatment group (32) 9.79 ± 0.93 9.03 ± 0.77## diastolic pressures (KPa)
Matched group (28) 9.34 ± 0.71 9.13 ± 0.67
Treatment group (32) 81.97 ± 8.17 82.52 ± 7.28 creatinines (μ mol/L)
Matched group (28) 84.89 ± 11.30 81.84 ± 6.32
Treatment group (32) 4.66 ± 1.19 4.60 ± 1.06# blood urea nitrogens (mmol/L)
Matched group (28) 5.24 ± 1.38 5.24 ± 1.12
Treatment group (32) 11.40 ± 3.55 10.75 ± 5.30 glutamate pyruvate transaminase (μ/L)
Matched group (28) 9.68 ± 3.50 13.22 ± 5.81
Treatment group (32) 12.77 ± 3.77 13.1 6 ± 4.15 total bilirubin (mol/L)
Matched group (28) 12.80 ± 4.95 11.70 ± 2.32
Treatment group (32) 4.54 ± 1.20 4.35 ± 1.27 bilirubin directs (mol/L)
Matched group (28) 4.32 ± 1.18 4.44 ± 0.73
Treatment group (32) 7.89 ± 2.57 8.29 ± 2.87 unconjugated bilirubins (mol/L)
Matched group (28) 7.98 ± 3.76 7.40 ± 2.15
Annotate: between two groups of * relatively;
#: compare before and after the medication;
*#：P＜0.05，##：P＜0.01
The clinical efficacy of medicine of the present invention has the following advantage that has:
(1) all can use many sick patients that plant the merging soft tissue injury, adapt to wide.
The patient who merges soft tissue injury by embodiment 5 treatments 200 routine fracture, dislocation, trauma infection contamination, soft tissue strain and contusion etc., male's 146 examples wherein, women's 54 examples, the oldest 77 years old, minimum 1.5 years old, damage location was the trunk extremity, wherein closed fracture or 122 examples of dislocating (accounting for 55.45%), soft tissue strain and contusion 19 examples (accounting for 8.6%), open fracture 44 examples (accounting for 20%), trauma infection contamination 35 examples (accounting for 15.91%).Therapeutic outcome sees the following form 24～25:
Each sick therapeutic evaluation classification fracture dislocation open fracture trauma infection contamination soft tissue strain and contusion of planting of table 24. embodiment 5 treatment adds up to produce effects 107 39 22 10 107 effective 15 2 12 8 37 invalid 03115 to add up to 122 44 35 19 220 obvious effective rates, 87.71% 88.64% 62.86% 52.63% 80.91% total effective rates 100% 93.18% 97.14% 94.74% 97.72%
The various damage individual event therapeutic evaluatioies of table 25. embodiment 5 treatments
Produce effects enabledisable total effective rate
Example number % example number % example number % example number % swelling 150 71.43 50 23.81 10 4.76 210 95.24 pain 166 79.05 40 19.05 4 1.91 210 98.10 ecchymosis 86 78.90 20 18.35 3 2.75 109 97.25 surface of a wound 57 72.15 16 20.25 6 7.60 79 92.41 red and swollen heat 680 70.83 25 26.04 3 3.13 96 96.88
Above-mentioned clinical observation shows: this medicine has definite curative effect to soft group of thin,tough silk swelling, pain, ecchymosis, local red and swollen heat pain and the wound healing that fracture, dislocation, open fracture, trauma infection contamination, soft tissue strain and contusion etc. cause.
(2) it is fast that embodiment has reducing swelling and alleviating pain, obviously reduces the advantage of traumatic infection chance, and its therapeutical effect is comprehensive.
Observe by contrast treatment with acute open soft tissue injury, external embodiment 5, acute open soft tissue injury 60 examples of 6 treatments, wherein 32 examples are organized in the embodiment treatment, medication 15～20 days, its total effective rate is 93.75%, nitrofural matched group 28 examples, its total effective rate is 85.71%, see Table 26～29, the treatment group is directly poor to reducing strong Ipsilateral week, the skin temperature difference and the partial stasis of blood of wound mouth (red) speckle, the wound surface scope, WBC all obviously is better than nitrofural group (P＜0.05), embodiment is in detumescence, pain relieving, blood stasis dispelling, recover local skin temperature, reducing wound surface suppurates, promptly occur obviously effect after 3 days in medication, and nitrofural in medication obviously effect (P＜0.05) appearred just after 7 days.The effect that shows embodiment is many-sided, it is further developing at wound early stage energy inflammation-inhibiting not only, and the middle and advanced stage in wound can promote disappearing of inflammation, quicken the absorption of local stasis of blood, improve the damaged tissue local blood circulation effectively, quicken pyrogenicity, cause the moving commentaries on classics of the pain factor, thereby reach pain relieving, the local skin temperature of reduction, promote tissue repair, the appearance that the opposing local woanded surface infects, advance wound repair.Thereby proved the merit of embodiment heat-clearing and toxic substances removing, reducing swelling and alleviating pain, blood circulation promoting and blood stasis dispelling, putrefaction-removing granulation-promoting objectively.Two groups to the curative effect of acute open soft tissue injury by contrast, and embodiment is that to have a reducing swelling and alleviating pain fast, obviously reduces the advantage of traumatic infection chance, and its therapeutical effect is comprehensive.
The comparison of table 26. liang group curative effect
The curative effect total effective rate
Group n
32 24 (75.00) 8 (18.75) 2 (6.25) 93.75 nitrofural matched groups 28 19 (67.85) 5 (17.86) 4 (14.29) 85.71 are organized in recovery from illness produce effects invalid (%) embodiment treatment
The table 27. liang open symptoms of soft tissue injuries that group is common, sign and lab testing are relatively
After the medication before the medication of observation index group
The poor treatment group 0.84 ± 0.47 in 3 days 7 days 15 days weeks footpath, (31) 1.18 ± 0.91, (32) 0.54 ± 0.71, (30) #* 0, (29) ##*, (cm) matched group 0.80 ± 0.61, (27) 1.37 ± 0.70, (25) ## 0.95 ± 0.80, (27) 0.16 ± 0.31, (25) the # stasis of blood, (red) speckle treatment group 28.44 ± 18.11, (29) 17.35 ± 18.16, (30) ## 6.59 ± 6.14, (28) ##* 0, (26) ##*, (cm
2) matched group 30.64 ± 19.40 (28) 26.10 ± 22.57 (26) 13.92 ± 12.27 (26) ## 0.42 ± 0.80 (21) ## Wound treating group 8.11 ± 6.38 (28) 2.62 ± 1.92 (29) * 1.45 ± 1.10 (27) ##* 0 (23) ## (cm
2) control group 6.68 ± 4.01 (24) 4.35 ± 3.48 (28) 2.63 ± 1.97 (26) ## 0 (19) ## skin temperature difference treatment group-0.60 ± 0.81 (32) 0.47 ± 0.89 (31) ## 0.29 ± 0.52 (30) ## 0.21 ± 0.44 (31) * ## (℃) control group-0.76 ± 1.02 (27) 0.11 ± 1.06 (27) ## 0.29 ± 1.00 (27) ##-0.07 ± 0.51 (25) #WBC treatment group, 8.47 ± 2.57 (31) 7.27 ± 1.52 (31) # 6.57 ± 1.10 (30) ##*, 7.69 ± 1.99 (30) # (* 109/L ) 8.15±1.98 ( 28 ) 7.82±2.03 ( 27 ) 7.48±1.78 ( 28 ) 7.58±1.74 ( 25 ) DC 70.62±10.52 ( 32 ) 68.97±6.97 ( 32 ) 68.94±7.21 ( 32 ) 67.97±7.82 ( 30 ) ( ％ ) 72.43±8.37 ( 28 ) 71.64±7.38 ( 28 ) 68.39±6.96 ( 28 ) # 66.16±8.02 ( 25 ) #T 36.77±0.50 ( 32 ) 36.49±0.44 ( 31 ) ## 36.43±0.44 ( 32 ) ## 36.46±0.43 ( 32 ) ## ( ℃ ) 36.98±0.34 ( 28 ) 36.59±0.40 ( 28 ) ## 36.61±0.50 ( 28 ) ## 36.55±0.49 ( 28 ) ## P 79.16±12.10 ( 32 ) 80.94±9.30 ( 32 ) 81.03±9.23 ( 32 ) 81.81±10 47 ( 32 ) ( / ) 79.48±8.23 ( 27 ) 78.18±7.91 ( 28 ) 77.70±6.09 ( 27 ) 77.50±4.87 ( 26 )
Annotate: *: treatment group matched group compares, #: compare * #:P＜0.05, ##:P＜0.01 before and after the group innerlich anwenden
Table 28. liang group is to the influence of pain
15 days pain degree treatment group treatment of control group group # treatment of control group group # treatment of control group group ## matched group * # after the medication in 7 days after the medication in 3 days after the medication before the medication
(32) severe 11100100 moderates 22 18 252100 slight 9 10 27 22 22 21 69 in (28) (32) (28) (32) (28) (32) (28) do not have 002185 26 19 anti-inflammatory rates (%), 00 6.25 3.75 25.00 17.86 81.25#* 67.86#*
Annotate: compare P＜0.05 before and after the # group innerlich anwenden;
* after the medication 15 days with medication after 3,7 days relatively, *: P＜0.05
Table 29. wound secretions situation and positive rate of bacteria
After the medication (my god) before the medication of index group
37 15 purulent secretion treatment groups, (32) 3.12, (1) 9.38, (3) * 28.12, (9) * 25.00, (8) positive rate, (%) matched group, (28) 3.57, (1) 28.57, (8) 50.00, (14) # 25.00, (7) secretions bacterize group, (32) 18.75, (6) 25.00, (8) 40.63, (13) 28.12, (9) cultivate positive rate, (%) matched group, (28) 21.43, (63) 35.71, (10) 42.86, (12) 21.43, (6)
Annotate: *: two form face purulent secretion positive rate X relatively
2Value is respectively 3.68 and 3.02,
The α value is near significant level;
#: compare #P＜0.05, positive routine number in the bracket before and after the medication.
Other embodiment of the present invention shows that having identical and akin curative effect to reach with embodiment 5, embodiment 6 does not all have obvious toxic and side effects.
The invention is not restricted to the foregoing description.
Medicine of the present invention dosage form for oral administration is also done investigation, showed akin curative effect.
Claims (13)
1. medicine for external use for the treatment of soft tissue injury is characterized in that this medicine for external use made by following medicine: Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi), Alumen, Mentholum, make water preparation, ointment, plaster or membrane dosage form; The weight ratio of each medicine is: 10～20 parts of Rhizoma Coptidis, 8～15 parts of Cortex Phellodendris, 8～15 parts of Fructus Gardeniaes, 8～15 parts of Radix Arnebiae (Radix Lithospermi)s, 2～5 parts of Alumens, 0.05～0.1 part of Mentholum.
2. the medicine for external use of treatment soft tissue injury according to claim 1 is characterized in that the weight ratio of each medicine is: 12～18 parts of Rhizoma Coptidis, 10～12 parts of Cortex Phellodendris, 10～12 parts of Fructus Gardeniaes, 10～12 parts of Radix Arnebiae (Radix Lithospermi)s, 3～4 parts of Alumens, 0.07～0.08 part of Mentholum.
3. the medicine for external use of treatment soft tissue injury according to claim 1 is characterized in that medicine of the present invention is the external water preparation.
4. according to the medicine for external use of claim 1 or 3 described treatment soft tissue injurys, it is characterized in that adding solubilizing agent in the external water preparation of the present invention.
5. according to the medicine for external use of claim 1 or 4 described treatment soft tissue injurys, the solubilizing agent that it is characterized in that external water preparation of the present invention is a glycerol.
6. the medicine for external use of treatment soft tissue injury according to claim 1 is characterized in that adding antiseptic in the external water preparation of the present invention.
7. according to the medicine for external use of claim 1 or 6 described treatment soft tissue injurys, the antiseptic that it is characterized in that external water preparation of the present invention is an ethylparaben.
8. according to the medicine for external use of claim 1 or 3 described treatment soft tissue injurys, the proportioning that it is characterized in that external water preparation of the present invention is: Rhizoma Coptidis 15.96kg, Cortex Phellodendri 11.4kg, Fructus Gardeniae 11.4kg, Radix Arnebiae (Radix Lithospermi) 11.4kg, Alumen 3.42kg, Mentholum 0.09kg, glycerol 45.87kg, ethylparaben 0.46kg add water and are made into 230～920 premium on currency agent.
9. according to the medicine for external use of claim 1 or 3 described treatment soft tissue injurys, it is characterized in that external water preparation of the present invention also adds Percutaneous absorption enhancer.
10. production method as the external water preparation of claim 1 treatment soft tissue injury may further comprise the steps:
A. get Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae pulverizing, add 10 times of amount 70% alcohol heating reflux 2 times, filter, filtering residue discards;
B. get Radix Arnebiae (Radix Lithospermi) in addition and be cut into 1～2cm segment, add 10 times of amount 70% alcohol at normal temperature and soak 2 times, filter, filtering residue discards;
C. Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) filtrate are merged, reclaim ethanol, add Alumen to the greatest extent;
D. get Mentholum, ethylparaben adds after with a small amount of 95% dissolve with ethanol, and capacity transfer fully stirs to 90～93% of capacity, leaves standstill 24 hours in 0～4 ℃, and filter press adds glycerol again, fully stirs;
E. use the microporous filter membrane degerming, aseptic subpackaged, get product.
11. the production method of the external water preparation of treatment soft tissue injury according to claim 10, the aperture that it is characterized in that microporous filter membrane are 0.45 μ m.
12. the production method of the external water preparation of treatment soft tissue injury according to claim 10, it is characterized in that pondage to the pharmaceutical preparation capacity 90～93% after, regulating pH is between 3.7～4.0.
13. the production method of the external water preparation of treatment soft tissue injury according to claim 10 is characterized in that Rhizoma Coptidis of the present invention, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) use water extraction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96123078A CN1056298C (en) | 1996-12-31 | 1996-12-31 | External use medicine for treating soft tissue injury and its producing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96123078A CN1056298C (en) | 1996-12-31 | 1996-12-31 | External use medicine for treating soft tissue injury and its producing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1215595A CN1215595A (en) | 1999-05-05 |
| CN1056298C true CN1056298C (en) | 2000-09-13 |
Family
ID=5127578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96123078A Expired - Lifetime CN1056298C (en) | 1996-12-31 | 1996-12-31 | External use medicine for treating soft tissue injury and its producing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056298C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693069B (en) * | 2009-08-06 | 2013-04-24 | 浙江普洛康裕天然药物有限公司 | Composition for preparing external preparation for treating soft tissue injuries and preparation method thereof |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101195010B (en) * | 2007-12-11 | 2011-09-21 | 徐欢欢 | Powder medicament for treating acute soft tissue injury |
| CN102920825B (en) * | 2012-11-08 | 2014-04-09 | 马俊龙 | Tissue regeneration promoting strengthening powder |
| CN106822321B (en) * | 2017-03-08 | 2020-06-23 | 佛山市中医院 | Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris |
| CN108653439A (en) * | 2018-06-11 | 2018-10-16 | 云南御之健医卫用品科技有限公司 | A kind of outer application disinfection oil and preparation method thereof |
| CN113577166B (en) * | 2021-08-26 | 2022-11-11 | 墨脱县人民医院 | Medicinal oil and preparation method thereof |
| CN114306710A (en) * | 2021-12-30 | 2022-04-12 | 佛山市中医院 | Medical dressing and preparation method thereof |
| CN118453746A (en) * | 2024-05-13 | 2024-08-09 | 盐源县中医医院 | A Chinese medicinal ointment for promoting blood circulation, reducing swelling and promoting tissue regeneration and a preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031174A (en) * | 1987-08-10 | 1989-02-22 | 石原产业株式会社 | Herbicidal combinations |
| CN1127129A (en) * | 1995-01-16 | 1996-07-24 | 徐永林 | External application medicine for burn and scald and preparing method |
-
1996
- 1996-12-31 CN CN96123078A patent/CN1056298C/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031174A (en) * | 1987-08-10 | 1989-02-22 | 石原产业株式会社 | Herbicidal combinations |
| CN1127129A (en) * | 1995-01-16 | 1996-07-24 | 徐永林 | External application medicine for burn and scald and preparing method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693069B (en) * | 2009-08-06 | 2013-04-24 | 浙江普洛康裕天然药物有限公司 | Composition for preparing external preparation for treating soft tissue injuries and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1215595A (en) | 1999-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN101028384A (en) | Medicinal composition for treating gynaecologic phlogosis, its production and quality controlling method | |
| CN1212134C (en) | Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process | |
| CN1879833A (en) | An wind-expelling ointment and method for preparing same | |
| CN1287830C (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN103251741B (en) | Chinese medicine composition for treating toxoplasmosisinswine, and preparation method and application thereof | |
| CN1686505A (en) | Chinese medicinal preparation for treating prostate disease and its production method | |
| CN1569071A (en) | Medicine for diminishing the inflammation and reducing the pain, subsiding swelling to dissipate indurated mass, dredging meridian to removing stagnation | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1698815A (en) | Chinese medicinal composite ointment, its preparation process, cataplasm thereof and method for preparing the same | |
| CN1240412C (en) | Chinese medicine compound preparation for treating piles and preparing process thereof | |
| CN109528868A (en) | A kind of Chinese medicine composition treats aphthae in preparation, the application in the drug of carbuncle swells furunculosis | |
| CN1589892A (en) | Medicinal composition for treating acute, chronic pharyngolaryngitis and its preparation method | |
| CN1772136A (en) | A kind of pharmaceutical composition and preparation method for treating tendon soft tissue injury and osteoarthropathy | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1319588C (en) | Theory and medicine for treating high blood fat, fatty liver, liver fibrosis and preparation method | |
| CN1552433A (en) | Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof | |
| CN1439416A (en) | Uterus-preserving hemostatic and preparation method thereof | |
| CN1745788A (en) | Traditional Chinese medicine preparation for treating infantile diarrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20000913 |
|
| EXPY | Termination of patent right or utility model |